Merck & CompanyvsSunshine Biopharma

MRK and SBFM stock compared: price, dividend, valuation and results, from SEC filings.

MRK

Merck & Company, Inc.

$147.94

Value $366B

+0.15%
MRK's page

SBFM

Sunshine Biopharma Inc.

$2.62

Value $2.2M

-2.96%
SBFM's page

Merck & Company (MRK) has a market value of $366B and Sunshine Biopharma (SBFM) $2.2M. Over the last year, with dividends, MRK moved +64.0% and SBFM -99.2%. Dividend yield: MRK 2.30%, SBFM none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    MRK$366B

    SBFM$2.2M

    MRK is 169,471 times SBFM

  • Revenue, 12 months

    MRK$67.4B

    SBFM$35M

    MRK is 1,905 times SBFM

  • Net income, 12 months

    MRK$2.5B

    SBFM-$6.2M

  • Operating margin

    MRK–

    SBFM-17.2%

  • ROIC

    MRK3.9%

    SBFM-19.3%

    23.1 points apart

  • P/E

    MRK149.1

    SBFM–

  • Dividend yield

    MRK2.3%

    SBFM0.0%

    2.3 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

MRK+59.0%

SBFM-100.0%

050100150202420252026
Returns by period
PeriodMRKWith dividendsSBFMWith dividends
1 year since November 14, 2025+64.0%Price +59.3%-99.2%Price -99.2%
3 years since November 16, 2023+59.0%+16.7% a yearPrice +45.1%-100.0%-97.1% a yearPrice -100.0%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

MRKMerck & CompanySBFMSunshine Biopharma

Valuation

MRKSBFM
Valuation
Price$147.94$2.62
Market value$366B$2.2M
Enterprise value (EV)$410B–
P/E149.1–
P/E, 5-year median14.8–
P/B8.20.1
EV/EBIT86.1–
Free cash flow yield4.0%–

Results and growth

MRKSBFM
Results and growth
Revenue, 12 months$67.4B$35M
Net income, 12 months$2.5B-$6.2M
Free cash flow, 12 months$14.7B-$6.0M
Earnings per share, 12 months$0.98-$170.83
Revenue growth, year on year1.3%4.1%
Revenue growth a year, past+9.4%over 5 years+247.7%over 5 years
EPS growth a year, past+21.2%over 5 years–

Margins and returns on capital

MRKSBFM
Margins and returns on capital
Gross margin71.8%30.4%
Operating margin–-17.2%
Net margin3.6%-17.5%
ROIC3.9%-19.3%
ROE5.2%-24.7%

Balance sheet

MRKSBFM
Balance sheet
Cash$9.7B$15M
Total debt$53.8B$627.6K
Net debt / EBITDA5.7–
Interest cover2.4×–

Dividends and buybacks

MRKSBFM
Dividends and buybacks
Dividend yield2.3%–
Dividend per share, 12 months$3.40–
Dividend growth a year, past+5.8%over 5 years–
Buyback yield1.4%–
Shareholder yield3.7%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: MRK or SBFM

Didn't find what you were looking for?

Ask us
Which is bigger, Merck & Company or Sunshine Biopharma?

By market value, Merck & Company ($366B) is about 169,470.7 times Sunshine Biopharma ($2.2M), at today's prices.

How did MRK and SBFM stock do over the last 3 years?

Since November 16, 2023, MRK's price moved +45.1% and SBFM's -100.0%. With dividends: MRK +59.0% (+16.7% a year), SBFM -100.0% (-97.1% a year). Past returns do not predict future ones.

Which pays the higher dividend, MRK or SBFM?

The dividend yield at today's price is 2.30% for Merck & Company and none for Sunshine Biopharma. Over the last twelve months they paid $3.40 and – per share.

Which has the higher profit margins, Merck & Company or Sunshine Biopharma?

Over the last twelve months, the net margin was 3.6% for Merck & Company and -17.5% for Sunshine Biopharma, and the operating margin – and -17.2%. Revenue was $67.4B and $35M.

Which is the better investment, Merck & Company or Sunshine Biopharma?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.